Articles tagged with Lymphoma
A study published by researchers at M.D. Anderson Cancer Center revealed that intense chemotherapy significantly reduces the risk of recurrence in young mantle cell lymphoma patients. In a median follow-up of seven years, 52% of patients aged 65 or younger achieved disease-free survival.
Mantle cell lymphoma cells rely on heat shock protein 90 to maintain their rapid growth. Researchers are using inhibitors to block this process, causing stress in the cells' machinery. The goal is to trigger apoptosis in cancer cells.
A new study reveals that poorer socioeconomic status increases mortality risk in non-Hodgkin lymphoma patients, while chemotherapy reduces the risk. Ethnic disparities are also observed, with African-Americans less likely to receive chemotherapy and living in poorer communities.
A research article compares CT findings in mesenteric tuberculosis and non-Hodgkin's lymphoma (NHL), revealing specific enhancement patterns and anatomic lymph node distribution. The 'sandwich sign' is more often found in NHL, aiding in differential diagnosis between tuberculosis and untreated NHL involving the small bowel mesentery.
Researchers found Rheb overexpression is sufficient to induce low-grade prostate neoplasias and contributes to lymphoma formation. Targeted inhibition of Rheb shows promise in counteracting tumor progression in both cancers.
A new study reveals that mantle cell lymphoma incidence is increasing, especially among men and Caucasians, with advanced stages detected in nearly 75% of patients. The research also highlights the need for better understanding of the disease's epidemiology and development of novel treatment agents.
Researchers at ESMO Conference Lugano report improved treatment outcomes for aggressive non-Hodgkin's lymphoma patients when chemotherapy is administered every 2 weeks, rather than every 3 weeks.
Researchers used PET scans to analyze 38 patients with non-Hodgkin's lymphoma treated with 90 ibritumomab tiuxetan. The study found that 89% of patients were in complete or partial remission after treatment, with a higher response rate for patients with limited cancer progression.
In a phase II clinical trial, 70% of patients with follicular lymphoma responded to treatment with galiximab and rituximab. The combination regimen achieved complete responses in 44% and partial responses in 26%. Further study is warranted to assess the efficacy and time-to-progression endpoint.
Researchers found that treatments for childhood Hodgkin's lymphoma increase the risk of dying from a second cancer or cardiovascular disease in adulthood. Women are especially vulnerable to breast cancer, while men are at risk of cardiovascular events.
A phase 1 clinical trial showed AME-133v had a potent tumor-halting response in patients with follicular lymphoma. The drug triggered signaling pathways within cells to slow or stop cancer growth, while causing minimal side effects.
A long-term study of twins has led USC researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein, interleukin-12. Lower levels of this protein may increase susceptibility to the disease.
Researchers at the University of Southern California found that combined positron emission tomography (PET) and computed tomography (CT) imaging yields greater accuracy when evaluating response to radiation therapy. This method helps identify complete responders and reduces the need for unnecessary chemotherapy treatments.
The study analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program and found that non-Hodgkin lymphoma patients showed significant improvements in five- and 10-year survival rates, with increases ranging from 26.8 to 27.1 percentage points across all age groups and tumor subtypes.
Researchers found that the antimalarial drug chloroquine effectively prevents cancer in mouse models of two human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia. Chloroquine inhibited the development of Myc-induced lymphomas and ATM-deficient mice, but not p53-deficient mice.
Researchers have found that the Myc protein can stop the production of at least 13 microRNAs, which help control gene expression. Re-introducing repressed miRNAs into cancer cells suppressed tumor growth in mice, raising hopes for a novel therapy approach.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
A new study has identified a direct link between Plasmodium falciparum antigens and Epstein-Barr virus (EBV) reactivation, increasing the risk of Burkitt lymphoma in children living in malaria-endemic areas. The researchers found that certain proteins from P. falciparum can spur latent EBV-infected cells into active production.
A University of Michigan study found that 86% of patients with follicular lymphoma survived after 8 years of treatment with Bexxar, a radioimmunotherapy drug. This success rate compares favorably to state-of-the-art chemotherapy regimens, making Bexxar an attractive option for patients.
Adding radioimmunotherapy to chemotherapy increased complete response rates for patients with follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma. Over 90% of study patients responded completely to the treatment, with limited side effects.
Alcohol drinking has been associated with a reduced risk of renal cell cancer. Childhood leukemia and lymphoma survivors face an elevated risk of secondary cancers, while treatment with clodronate did not improve survival for men with localized prostate cancer.
A study found that hepatitis C virus (HCV) infection increases the risk of non-Hodgkin lymphoma by 20-30% and Waldenström macroglobulinemia by nearly three-fold. HCV is also linked to an increased risk of nonmalignant plasma cell disorders.
People infected with hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas, including non-Hodgkin's lymphoma and Waldenström's macroglobulinemia. The risk was found to be 20-30% higher for HCV-infected patients compared to uninfected patients.
A study by radiologists at the University of Minnesota found that PET-CT detects muscular lymphoma more effectively than CT alone, revealing muscle involvement that may be overlooked. This breakthrough suggests that incorporating PET-CT into imaging protocols can lead to more accurate diagnoses and treatment plans.
Researchers at the University of Helsinki have discovered a new effective treatment modality for KSHV-infected lymphomas by reactivating the p53 pathway. The study shows that Nutlin-3a, a small-molecule inhibitor, selectively induces massive apoptosis in PEL cells.
Researchers discovered Nutlin-3a induces apoptosis in human PEL cell lines by disrupting LANA-p53 interaction, causing substantial tumor regression in mice with established PEL. This reactivation of the p53 pathway may provide a viable therapeutic option for individuals with KSHV-induced lymphomas.
International team develops standardized guidelines for assessing lymphoma treatment response, incorporating new imaging technologies. The revised guidelines aim to improve therapies and facilitate the development of new treatments.
A new study found that calcium supplements can reduce the risk of colorectal adenoma recurrence by up to 5 years after stopping supplementation. In contrast, antioxidant supplements did not show a significant effect on gastric cancer risk.
A recent study found that Hodgkin's lymphoma survivors who undergo lipid screening every five years live six months longer than those without screening. The study suggests that regular cholesterol screening is a cost-effective procedure to reduce the risk of heart disease in these patients.
Researchers found that doxycycline effectively regresses lymphoma in both positive and negative patients for Chlamydia psittaci, offering a safe alternative to chemotherapy and radiation. The study showed a 66% rate of disease-free survival among patients treated with doxycycline.
Radiation therapy significantly reduces risk of subsequent mastectomy and invasive breast cancer in both low- and high-risk patients with ductal carcinoma in situ (DCIS). Autoimmune conditions are also associated with increased risk of Hodgkin lymphoma, according to two new studies.
A new analysis of ACT trials found that UC patients in clinical remission had significantly higher rates of employment compared to those not in remission. Patients treated with REMICADE experienced a greater percentage of being employed at weeks 30 and 54, with 20.6% vs 8.3% for non-remitted patients.
Researchers found combined therapy improved survival rates for patients with AIDS-related lymphoma, comparable to non-HIV patients with lymphoma treated with CHOP. For standard-risk ARL patients, 79% achieved complete remission and 50% survived after 47 months.
Researchers found a substantial link between severe rheumatoid arthritis and increased risk of lymphoma. Patients with high RA activity experienced a 70-fold increase in lymphoma risk, while those with low activity had an 8-fold increase.
Researchers found that STAT1 expression was lower in SCCHN tumors than in normal tissue, and increasing STAT1 expression led to suppressed tumor growth. The study also suggests that STAT1 works as a tumor suppressor for SCCHN cells, but when its expression is lowered, SCCHN tumors grow.
Researchers have found a potential association between high blood levels of PCBs and furans with an increased risk of developing non-Hodgkin lymphoma. The study analyzed blood samples from 100 healthy volunteers and 100 non-Hodgkin lymphoma patients, revealing a link between three specific molecular forms of PCBs and cancer development.
ECCO 13 study investigates post-treatment parenthood success rates in Hodgkin's lymphoma patients, with radiotherapy and chemotherapy linked to higher pregnancy success. The research highlights the importance of preserving fertility in young cancer survivors.
Recent studies have shown that combining standard chemotherapy with new monoclonal antibody therapies can significantly improve survival rates for patients with follicular lymphoma. The latest study, led by Richard I. Fisher, found a 91% four-year survival rate for patients treated with this regimen.
Researchers studied 1,131 patients with early-stage Hodgkin's lymphoma and found that reducing the radiation dose from 30 Gy to 20 Gy significantly improved patient outcomes. Over 98% of patients experienced complete remission, while side effects were reduced.
Researchers found no link between breast-feeding and adult cancer risk, but high red meat consumption is associated with increased pancreatic cancer risk. A new vaccine approach may enhance tumor-specific immune response when combined with chemotherapy.
A model predicts that young women treated for Hodgkin lymphoma are at increased risk of developing breast cancer, with risks rising with age and radiation exposure. Current treatment guidelines may be reconsidered to minimize these risks.
Researchers found that viral protein vFLIP K13 actively promotes cancer cell growth through the NF-?B pathway, leading to increased lymphoma formation in transgenic mice. The study provides a promising new target for novel therapies against HHV8-associated tumors.
A Yale University study found that drinking alcohol may lower the risk of non-Hodgkin's lymphoma, particularly for Burkitt's lymphoma subtype. The study analyzed data from 15,175 individuals and found no significant association between age, sex, family history, or cigarette smoking with reduced risk.
Researchers are exploring a new approach to treating blood cancers by exploiting the natural process of programmed cell death, known as apoptosis. This could potentially kill tumour cells more effectively and improve treatment outcomes. The Leukemia and Lymphoma Society is providing strong support for this research.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
A pooled analysis of 15,000 individuals found that current drinkers had a 27% lower risk of non-Hodgkin's lymphoma compared to non-drinkers. The risk did not vary with alcohol consumption type or age of onset, but was lowest for Burkitt's lymphoma subtype.
A study of 11 patients with non-Hodgkin's lymphoma who have failed standard chemotherapy found that Zevalin was effective in inducing partial and complete responses in three patients. The treatment was well-tolerated, with side effects including thrombocytopenia and neutropenia.
Researchers found that most imaging scans are unnecessary and can be avoided by confirming medication delivery within 24 hours of indium 111-labeled Zevalin injection. This simplifies treatment and improves patient compliance.
Researchers found significantly higher risks of non-Hodgkin's lymphoma and multiple myeloma among HCV patients in Sweden. The risk increases with the duration of HCV infection, suggesting that long-lasting infection may contribute to cancer development.
A new radioactive antibody treatment called Bexxar has shown promising results in a study, rivaling traditional chemotherapy regimens for follicular lymphoma. The treatment achieved a 95% response rate and 75% complete remission in patients with advanced-stage disease.
A large-scale study found that frequent exposure to ultraviolet rays from the sun, lamps, and solariums reduces the risk of developing non-Hodgkin's lymphoma by 30-40%. Researchers analyzed responses from over 6,000 patients and healthy individuals in Sweden and Denmark.
A recent study found that only 37% of patients with colorectal cancer received adequate lymph node evaluation, highlighting the need for improved surgical care and pathologic assessment. Additionally, research on non-Hodgkin lymphoma and obesity suggests no association between body mass index and overall risk of either disease.
Research findings indicate that increased sun exposure is associated with improved melanoma survival, while decreased UV radiation exposure may lower non-Hodgkin lymphoma risk. These studies provide new evidence for the potential beneficial effects of sunlight on cancer incidence and outcome.
Researchers at City of Hope Cancer Center have successfully treated 17 out of 20 HIV-positive patients with refractory lymphoma using high-dose chemotherapy and autologous stem cell rescue. The study shows promising results with an 85% survival rate, paving the way for further investigation into this potential cure.
A USC/Norris Comprehensive Cancer Center study reveals significant differences in survival rates between HIV-related lymphoma types, including DLCL and SNC. The research suggests that optimal therapy may differ for these sub-types of disease.
Researchers analyzed 191 untreated follicular lymphoma patients and developed a model that divides patients into four groups with disparate average survival rates. The model uses gene expression patterns from non-malignant immune cells to predict patient risk, suggesting new therapeutic approaches.
A population-based case-control study found no association between SV40 exposure and increased risk of NHL. SV40 seropositivity was detected in 7-10% of patients and less than 2% of controls, indicating a possible cross-reactivity with related human polyomaviruses.
Researchers developed a new cancer treatment combining radioimmunotherapy with conventional chemotherapy, achieving complete remission in 72% of patients with follicular non-Hodgkin's lymphoma. The approach may improve treatment outcomes by targeting remaining cancer cells after chemotherapy.
Researchers developed a sequential radioimmunotherapy and chemotherapy approach, achieving a 75% overall response rate and 90% complete remission rate in patients with advanced mantle cell lymphoma. The study's findings suggest this novel treatment may be a promising advance for the disease.
A study by Rockefeller University researchers reveals that a single molecular pathway controls both cell growth and death in a type of lymphoma cancer. The NF-kappa B signaling pathway, responsible for promoting cell growth, also regulates the p53 tumor suppressor protein's function, which normally destroys harmful cells.